Amsterdam Molecular Therapeutics Announces Management Changes in light of refocused strategy
Amsterdam Molecular Therapeutics announced a number of management changes. Piers Morgan (age 43) has been appointed Chief Financial Officer, effective December 1, 2009. Hans Preusting, PhD (age 47), Director process development & Manufacturing, will take up the responsibility for Operations and project management, also effective December 1. These changes reflect the refocused strategy of the company.
Piers Morgan is a University of Cambridge graduate (MA in Law and Management Studies), who received his ACA Qualification while at PriceWaterhouseCoopers, and who worked in M&A advisory with Close Brothers Corporate Finance and Ernst & Young before starting his career in biotechnology. He was Finance Director for Arrow Therapeutics where he successfully raised equity and debt capital, became CFO of BioAlliance Pharma SA in Paris, France, where he led the company’s IPO on Euronext, and recently was CFO and CBO at Phytopharm plc in the UK. He will succeed André Verwei, who was as AMT’s CFO as from 2005.
Before joining AMT in 2006, Hans Preusting had more than 14 years of experience in the production process of biologicals at Gist-Brocades, DSM Biologics and Solvay Pharmaceuticals. He will take up the operational responsibilities of Dr Anthony Gringeri, who resigned from the position of Chief Operating Officer to return to his home country, the United States.
Other news from the department people
